Drug intelligence / Profile preview

hPLTs-03

Development stage: Preclinical
Lead developer: HemaCell Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

hPLTs-03 is an ex vivo manufactured platelet cell therapy derived from hematopoietic stem and progenitor cells (HSPCs), developed by HemaCell Therapeutics (Xue Ji Bio). It is specifically designed as an AB-type platelet product for the treatment of thrombocytopenia. The production process involves the differentiation of HSPCs into megakaryocytes, which then undergo proplatelet formation and abscission to release functional platelets. As an AB-type product, it serves as a universal plasma-compatible platelet source. The therapy aims to address the limitations of donor-derived platelet transfusions, such as supply shortages, short shelf life, and risk of pathogen transmission.

Other names: hPLTs-03 (AB-type)HSPC-derived platelet therapy (AB-type)

Beyond the preview

Go deeper on hPLTs-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hPLTs-03.

Explore the full profile